Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Publication Date: April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...agnosis

...nosed ER-positive, HER2-negative Brea...

...ype DX (21-gene recurrence score)...

...tion 1.1If a patient has node-negative breast ca...

....2In the group of patients in Recommendation...

...ion 1.3In the group of patients in Recom...

...ommendation 1.4If a patient is postmenopaus...

...1.5In the group of patients in Recommendat...

...1.6If a patient is premenopausal and has node-posi...

...on 1.7If a patient has node-positi...

MammaPrint (70-gene signatu...

...ommendation 1.8If a patient is older tha...

...commendation 1.9If a patient is 50 years of age or...

...ndation 1.10If a patient has low clinical risk, re...

...mmendation 1.11If a patient has node-posit...

...ndoPredict (12-gene risk sc...

....12If a patient is postmenopausal and h...

....13If a patient is premenopausal and has br...

...ion 1.14If a patient has breast cancer wit...

...rosigna (PAM...

...ndation 1.15If a patient is postmenopaus...

...commendation 1.16If a patient is premenopausal,...

...endation 1.17If a patient is postmenopausal an...

...tion 1.18If a patient has node-positive breas...

Mammostrat

...insufficient evidence to recommend use of Mammos...

...Cancer Index (BCI)...

...atient has ER-positive, HER2-negative, node-neg...

...a patient has ER-positive, HER2-negative, node-po...

...i67

...mendation 1.19If a patient is postmeno...

...ecommendation 1.20If a patient is postmenopausal a...

...ecommendation 1.21Despite the limitat...

...histochemistry 4 (IHC4)...

...ommendation 1.22If a patient has node-negative...

...and PAI-...

...has ER-positive, HER2-negative (no...

If a patient has HER2-positive breast cancer...


...ed Endocrine Therapy For ER Recepto...

...e DX, EndoPredict, Prosigna, Ki67,...

...ndation 1.23If a patient has node-negative brea...

...CI

...ation 1.24If a patient has node-negative or...

...commendation 1.25If a patient has no...

...l Treatment Score post-5 Years (CTS5)

...dation 1.26If a patient is postmenopausal and had...


...-positive Breast Cancer or T...

...EndoPredict, MammaPrint, BCI, Prosigna, Ki6...

...ation 1.27If a patient has HER2-posi...


Emerging Biom...

...-Infiltrating Lymphocytes (TI...

...1.28If a patient has node-negative or node-positi...

...L1 Testing...

Recommendation 1.29If a patient has node-neg...

...ng Tumor Cells (CTC)...

...mmendation 1.30If a patient has node-negati...

...ating Tumor DNA (ctDNA)...

...ion 1.31If a patient has node-negative or node...


...1. Breast Cancer Biomarkers to Guide A...


...igure 1. Algorithm on Biomarkers to Guide Dec...


...Classification of Patients According...


...elieves that cancer clinical trials are vit...